- VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders
- PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder
- Company sees potential to displace benzodiazepines currently being used to treat multiple anxiety disorders
- Strategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed warnings on all benzodiazepines to highlight risks of abuse, misuse, addiction, and physical dependence
- Benzodiazepine epidemic is as worrisome as the opioid epidemic – 92 million benzodiazepine prescriptions in 2019 according to the FDA
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and several neurological disorders. The company’s product portfolio consists of three novel drug candidates which seek to target a wide variety of central nervous system (“CNS”) disorders through medications with potential to not only be effective but also present fewer side-effects and safety concerns relative to the current standard of care. Its initiative relating to anxiety disorders has unique potential to pay dividends following recent actions taken by the U.S. Food and Drug Administration (“FDA”) involving benzodiazepines, a class of drugs widely used to treat anxiety disorders, as well as insomnia and seizures.
In late September 2020, the FDA announced that it would require the boxed warning on all benzodiazepines to be updated to describe the risks of. . .
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
